The EMA’s scientific advice to pharma companies is a conflict of interest, says industry coalition

15 July 2014

A coalition of major European medicines advocates has criticized the European Medicines Agency for providing confidential ‘advice’ to pharma companies in exchange for fees, to give them guidance on their development plans for new drugs.

The EMA is attempting to extend this practice to national health technology assessment bodies in the European Union, as stated in its public consultation on ‘Best practice guidance for pilot EMA health technology assessment parallel scientific advice procedures’.

The coalition, made up of Health Action International Europe, the International Society of Drug Bulletins, the Medicines in Europe Forum and the Association International de la Mutualité, believes this constitutes a conflict of interest.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >